Global GLP-1 Receptor Antagonist Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Global GLP-1 Receptor Antagonist Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

GLP-1 receptor antagonists are a class of drugs used to treat metabolic diseases such as type 2 diabetes and obesity. They act on the GLP-1 receptor and inhibit the binding of GLP-1 to its receptor, thus blocking the biological effects of GLP-1. These drugs reduce insulin secretion by reducing the effects of GLP-1 and are often used to control blood sugar levels and weight. GLP-1 receptor antagonists are the opposite of GLP-1 receptor agonists, which are drugs that stimulate GLP-1 receptors and promote the biological effects of GLP-1.

According to our (Global Info Research) latest study, the global GLP-1 Receptor Antagonist market size was valued at US$ 3641 million in 2023 and is forecast to a readjusted size of USD 5711 million by 2030 with a CAGR of 6.6% during review period.

From the perspective of market size and growth trends, the GLP-1 drug market is growing rapidly. It has achieved great success in sales due to its excellent patient compliance. Take dulaglutide and semaglutide as examples. The global sales of these two drugs in 2022 will reach US$7.44 billion and US$9.342 billion respectively. In addition, the market value of two major pharmaceutical companies, Novo Nordisk and Eli Lilly, has soared due to the popularity of GLP-1 drugs. In the diabetes drug market, GLP-1 drugs have a market share of 39%, surpassing insulin to become the largest type of diabetes treatment drug in the world. In general, the market for GLP-1 receptor antagonists (or GLP-1 receptor agonists) is developing rapidly, and long-acting and oral administration are the main development trends in the future.

This report is a detailed and comprehensive analysis for global GLP-1 Receptor Antagonist market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.

Key Features:

Global GLP-1 Receptor Antagonist market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2019-2030

Global GLP-1 Receptor Antagonist market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2019-2030

Global GLP-1 Receptor Antagonist market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2019-2030

Global GLP-1 Receptor Antagonist market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (US$/Dose), 2019-2024

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for GLP-1 Receptor Antagonist

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global GLP-1 Receptor Antagonist market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk, AstraZeneca, Sanofi, Eli Lilly, Bayer, Merck, Shionogi, Pfizer, Jiangsu Hengrui Pharmaceuticals, Shanghai Fosun Pharmaceutical (Group), etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

GLP-1 Receptor Antagonist market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Injection
Oral Agent

Market segment by Application
Diabetes Treatment
Research
Other

Major players covered
Novo Nordisk
AstraZeneca
Sanofi
Eli Lilly
Bayer
Merck
Shionogi
Pfizer
Jiangsu Hengrui Pharmaceuticals
Shanghai Fosun Pharmaceutical (Group)
Shanghai Pharmaceutical Industry Research Institute

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe GLP-1 Receptor Antagonist product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of GLP-1 Receptor Antagonist, with price, sales quantity, revenue, and global market share of GLP-1 Receptor Antagonist from 2019 to 2024.

Chapter 3, the GLP-1 Receptor Antagonist competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the GLP-1 Receptor Antagonist breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2019 to 2030.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and GLP-1 Receptor Antagonist market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2030.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of GLP-1 Receptor Antagonist.

Chapter 14 and 15, to describe GLP-1 Receptor Antagonist sales channel, distributors, customers, research findings and conclusion.